Biogen (BIIB) PT Raised to $290 at Goldman Sachs

October 23, 2019 8:58 AM

Goldman Sachs analyst Terence Flynn raised the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $257.00) while maintaining a Neutral rating.

No results found